Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

UBX


Top 10 Correlated ETFs

UBX


Top 10 Correlated Stocks

UBX


In the News

07:00 30 Sep 2022 UBX

The Three Best Anti-Aging Stocks to Buy in September

Anti-aging stocks have not proven immune to poor market conditions that have plagued the broader biotech industry. The biotech industry remains hampered by the same bleak economic conditions as those affecting growth companies.

08:00 30 Sep 2022 UBX

UNITY Biotechnology to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will participate in the following investor conferences in September.

11:17 30 Sep 2022 UBX

Bears are Losing Control Over UNITY Biotechnology, Inc. (UBX), Here's Why It's a 'Buy' Now

UNITY Biotechnology, Inc. (UBX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

06:00 30 Sep 2022 UBX

Hot Penny Stocks to Add to Your Watchlist Right Now

Here's what you need to know about trading penny stocks on August 15th The post Hot Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

11:05 30 Sep 2022 UBX

Why Is Unity Biotechnology (UBX) Stock Up 71% Today?

Source: everything possible / Shutterstock.com Unity Biotechnology (NASDAQ: UBX ) stock is surging higher on Friday following the release of its earnings report for the second quarter of 2022. That report starts with the company's current cash position sitting at $64.5 million.

09:16 30 Sep 2022 UBX

Unity Biotechnology (UBX) Stock: Why It Skyrocketed Over 120% Today

The stock price of Unity Biotechnology (UBX) skyrocketed over 120% pre-market today. This is why.

04:00 30 Sep 2022 UBX

UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting

SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that 24-week clinical data results from the Phase 1 study of its lead senolytic candidate, UBX1325, in patients with diabetic macular edema and wet age-related macular degeneration will be presented at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting 2022, being held July 13-16, 2022. Details of the presentations are as follows:

12:35 30 Sep 2022 UBX

Why Did Mizuho Upgrade This Biotech Stock Focused On Age-Related Eye Diseases?

Mizuho upgraded Unity Biotechnology Inc (NASDAQ: UBX) to Buy from Neutral with a price target of $7, up from $5 after Unity announced longer-term Phase 1 data for UBX1325 in diabetic macular edema (DME) and wet age-related macular degeneration (AMD). Analyst Salim Syed expects some investor sentiment shift to begin at this point for this "underfollowed" stock.

08:00 30 Sep 2022 UBX

UNITY Biotechnology Reports Granting of New Employment Inducement Awards

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from September 21, 2021, through October 5, 2021, the Compensation Committee of the Board of Directors (the “Board”) granted 4 new employees stock-based awards covering an aggregate of 138,500 shares of UNITY common stock, including options to purchase an aggregate of 138,500 shares of UNITY common stock. The stock-based awards were granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).

03:52 30 Sep 2022 UBX

Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate

Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and wet age-related macular degeneration (AMD), for whom anti-VEGF therapy was no longer considered beneficial.  The data show strong and sustained responses following a single injection of UBX1325.

Financial details

Company Rating
Neutral
Market Cap
56.79M
Income
-48.45M
Revenue
236K
Book val./share
0.58
Cash/share
0.93
Dividend
-
Dividend %
-
Employees
65
Optionable
No
Shortable
Yes
Earnings
08 Nov 2022
P/E
-0.59
Forward P/E
-
PEG
0.1
P/S
120.18
P/B
0.71
P/C
0.44
P/FCF
-0.68
Quick Ratio
3.93
Current Ratio
4.13
Debt / Equity
1.03
LT Debt / Equity
1.03
-
-
EPS (TTM)
-0.77
EPS next Y
-
EPS next Q
-
EPS this Y
-99.94%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-76.41%
Revenue last 5Y
-67.8%
Revenue Q/Q
-
EPS Q/Q
-32.14%
-
-
-
-
SMA20
-20.75%
SMA50
-37.31%
SMA100
-53.33%
Inst Own
13.93%
Inst Trans
-8.67%
ROA
-50%
ROE
-93%
ROC
-0.68%
Gross Margin
100%
Oper. Margin
-23411%
Profit Margin
-20530%
Payout
-
Shs Outstand
140.23M
Shs Float
63.62M
-
-
-
-
Target Price
8
52W Range
0.39-3.64
52W High
-
52W Low
-
RSI
37.69
Rel Volume
0.13
Avg Volume
3.91M
Volume
524.61K
Perf Week
-8.53%
Perf Month
-57.78%
Perf Quarter
-64.99%
Perf Half Y
-65.87%
-
-
-
-
Beta
0.721037
-
-
Volatility
0.01%, 0.06%
Prev Close
-4.16%
Price
0.4096
Change
2.91%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
0000
Net income per share
-2.7-1.88-1.840
Operating cash flow per share
-2-1.66-1.540
Free cash flow per share
-2.05-1.7-1.550
Cash per share
6.052.921.920.59
Book value per share
5.682.771.631.07
Tangible book value per share
5.682.771.631.07
Share holders equity per share
5.682.771.631.07
Interest debt per share
000.60.92
Market cap
323.13M265.68M303.92M60.84M
Enterprise value
307.73M228.2M315.14M79.49M
P/E ratio
-4.23-3.23-3.24-1K
Price to sales ratio
00012.72K
POCF ratio
-5.71-3.67-3.880
PFCF ratio
-5.58-3.59-3.850
P/B Ratio
2.012.23.671.02
PTB ratio
2.012.23.671.02
EV to sales
00016.62K
Enterprise value over EBITDA
-4.23-2.58-3.48-1.24K
EV to operating cash flow
-5.43-3.15-4.020
EV to free cash flow
-5.32-3.08-3.990
Earnings yield
-0.24-0.31-0.310
Free cash flow yield
-0.18-0.28-0.260
Debt to equity
000.30.81
Debt to assets
0.110.20.470.52
Net debt to EBITDA
0.210.42-0.12-291.9
Current ratio
10.437.526.975.45
Interest coverage
00-72.717.84K
Income quality
0.740.880.830
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0004.82
Research and developement to revenue
0008.03
Intangibles to total assets
0000
Capex to operating cash flow
0.020.020.010
Capex to revenue
0000
Capex to depreciation
-0.58-0.6-0.190
Stock based compensation to revenue
0000
Graham number
18.5910.838.220.16
ROIC
-0.48-0.67-0.66-0.52
Return on tangible assets
-0.42-0.54-0.60
Graham Net
5.322.220.48-0.58
Working capital
156.38M112.27M86.4M73.89M
Tangible asset value
0000
Net current asset value
152.28M98.97M27.43M25.36M
Invested capital
000.350.87
Average receivables
0000
Average payables
3.7M3.87M2.56M2.27M
Average inventory
0000
Days sales outstanding
0000
Days payables outstanding
0000
Days of inventory on hand
0000
Receivables turnover
0000
Payables turnover
0000
Inventory turnover
0000
ROE
-0.48-0.68-1.130
Capex per share
-0.04-0.04-0.010

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-06-30
Revenue per share
00000
Net income per share
-0.32-0.30-0.28-0.19
Operating cash flow per share
-0.24-0.210-0.22-0.21
Free cash flow per share
-0.25-0.210-0.22-0.21
Cash per share
1.531.460.561.170.93
Book value per share
1.21.041.010.750.58
Tangible book value per share
1.21.041.010.750.58
Share holders equity per share
1.21.041.010.750.58
Interest debt per share
1.051.020.880.730.71
Market cap
254.55M166.31M85.78M75.63M39.02M
Enterprise value
297.98M200.21M104.43M107.9M67.91M
P/E ratio
-3.57-2.53429.13-1-0.74
Price to sales ratio
0017.93M0165.34
POCF ratio
-19.02-14.390-5.05-2.63
PFCF ratio
-18.91-14.270-5.05-2.63
P/B Ratio
3.862.881.441.490.98
PTB ratio
3.862.881.441.490.98
EV to sales
0021.83M0287.75
Enterprise value over EBITDA
-18.28-13.392.19K-6.17-5.84
EV to operating cash flow
-22.26-17.330-7.21-4.58
EV to free cash flow
-22.14-17.180-7.21-4.57
Earnings yield
-0.07-0.10-0.25-0.34
Free cash flow yield
-0.05-0.070-0.2-0.38
Debt to equity
0.860.950.810.871.03
Debt to assets
0.520.540.520.550.59
Net debt to EBITDA
-2.66-2.27391.73-1.85-2.48
Current ratio
6.546.535.454.554.13
Interest coverage
-21.68-18.724.2K-22.61-13.71
Income quality
0.750.700.791.13
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00-3.75K020.94
Research and developement to revenue
00-6.01K032
Intangibles to total assets
00000
Capex to operating cash flow
0.010.01000.01
Capex to revenue
0000-0.64
Capex to depreciation
-0.1-0.1400-0.25
Stock based compensation to revenue
00009.53
Graham number
2.962.640.142.181.57
ROIC
-0.14-0.13-0.09-0.19-0.15
Return on tangible assets
-0.13-0.130-0.17-0.13
Graham Net
0.250.23-0.550.260.1
Working capital
74.21M71.75M73.89M63.58M51.4M
Tangible asset value
00000
Net current asset value
17.26M16.77M25.36M19.71M10.16M
Invested capital
0.860.970.870.961.21
Average receivables
00000
Average payables
2.61M2.55M2.65M3.32M2.38M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.27-0.280-0.37-0.33
Capex per share
00000

Frequently Asked Questions

What is Unity Biotechnology, Inc. stock symbol ?

Unity Biotechnology, Inc. is a US stock , located in Brisbane california of California and trading under the symbol UBX

Is Unity Biotechnology, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $8. The lowest prediction is $8 and the highest is $8

What is UBX stock prediction ?

With a median analyst target price of $8, 2 stock analysts have made 2 forecasts in last 90 days. $8 is the lowest and $8 is the greatest projection.

What is Unity Biotechnology, Inc. stock quote today ?

Unity Biotechnology, Inc. stock price is $0.4096 today.

Is Unity Biotechnology, Inc. stock public?

Yes, Unity Biotechnology, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap